Lipoprotein(a) in clinical practice: From genetic risk assessment to therapeutic silencing

doi:10.5528/wjtm.124606

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 4

This Article

(3)

(2)

(0)

(160)

Peer-Review Report of This Article

Journal Information of This Article

Publication Name

World Journal of Translational Medicine

ISSN

2220-6132

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Transl Med. Nov 28, 2026; 12(4): 124606
Published online Nov 28, 2026. doi: 10.5528/wjtm.124606

Full Size Figure Download Figure

Figure 1 Schematic representation of the structural organization of lipoprotein(a). LDL: Low-density lipoprotein; ApoB-100: Apolipoprotein B-100; KIV: Kringle IV.

Citation: Feliciano LD, Freire JPC, Lopes CF, Lima PHM, Costa JMC, de Melo FF. Lipoprotein(a) in clinical practice: From genetic risk assessment to therapeutic silencing. World J Transl Med 2026; 12(4): 124606
URL: https://www.wjgnet.com/2220-6132/full/v12/i4/124606.htm
DOI: https://dx.doi.org/10.5528/wjtm.124606

Feliciano LD, Freire JPC, Lopes CF, Lima PHM, Costa JMC, de Melo FF. Lipoprotein(a) in clinical practice: From genetic risk assessment to therapeutic silencing. World J Transl Med 2026; 12(4): 124606 [DOI: 10.5528/wjtm.124606]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.